Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 28:11:1756284818800307.
doi: 10.1177/1756284818800307. eCollection 2018.

Rifaximin has the potential to prevent complications of cirrhosis

Steven L Flamm  1 , Kevin D Mullen  2 , Zeev Heimanson  3 , Arun J Sanyal  4
Affiliations

Rifaximin has the potential to prevent complications of cirrhosis

Steven L Flamm et al. Therap Adv Gastroenterol. .

Abstract

Background: Cirrhosis-related complications are associated with poor prognosis. With our analyses, we examined the potential benefit of rifaximin in reducing the risk of developing cirrhosis-related complications.

Methods: Adults with cirrhosis and hepatic encephalopathy (HE) in remission were randomly assigned to receive rifaximin 550 mg twice daily or placebo for 6 months with concomitant lactulose permitted. Post hoc analyses examined time to cirrhosis-related complications (HE, spontaneous bacterial peritonitis (SBP), variceal bleeding, acute kidney injury/hepatorenal syndrome). Subgroup analyses evaluated efficacy for select baseline disease characteristics.

Results: Of patients receiving rifaximin (n = 140) and placebo (n = 159), 53.6% and 49.1%, respectively, had baseline Model for End-Stage Liver Disease (MELD) score ⩾ 12 and international normalized ratio (INR) ⩾ 1.2. Baseline ascites was observed in 36.4% (rifaximin) and 34.6% (placebo) of patients. In patients with MELD score ⩾ 12 and INR ⩾ 1.2, rifaximin reduced the relative risk (RR) of any first complication experienced during trial by 59% [hazard ratio (HR) = 0.41, 95% confidence interval (CI): 0.25-0.67; p < 0.001] versus placebo. For patients with baseline ascites, rifaximin reduced the RR of any first complication experienced during trial by 42% versus placebo (HR = 0.58, 95% CI: 0.34-1.0; p = 0.045). For some subgroups, there was a decrease in RR of complications of SBP, variceal bleeding, and acute kidney injury/hepatorenal syndrome with rifaximin versus placebo, although there were few events reported in the study.

Conclusion: Rifaximin may reduce the incidence of cirrhosis-related complications and the recurrence of overt HE.[ClinicalTrials.gov identifier: NCT00298038.].

Keywords: antibiotic; cirrhosis; decompensation; hepatic encephalopathy; rifaximin.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: SL Flamm is a consultant and has served on the speakers’ bureau for AbbVie, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Merck & Co., Inc., and Salix Pharmaceuticals; and has received research support from AbbVie, Gilead Sciences, Inc., and Intercept Pharmaceuticals, Inc. KD Mullen has served as a consultant for Salix Pharmaceuticals and Norgine. Z Heimanson is an employee of Salix Pharmaceuticals. AJ Sanyal has stock options in Genfit and is the president of Sanyal Biotechnology. He has served as a consultant to AbbVie, AstraZeneca, Bristol-Myers Squibb Company, DURECT Corporation, Enanta Pharmaceuticals, Inc., Galmed Pharmaceuticals Ltd., Genfit, Gilead Sciences, Inc., Ikaria, Immuron, Intercept Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Nitto Denko Corporation, Novartis, Salix Pharmaceuticals, and Zafgen.

Figures

Figure 1.
Figure 1.
Time to a first complication of cirrhosis experienced during the trial by treatment group and baseline disease severity. (a) All complications of cirrhosis in patients with MELD score ⩾ 12 and INR ⩾1.2; (b) non-HE complications of cirrhosis in patients with MELD score ⩾ 12 and INR ⩾ 1.2; and (c) all complications of cirrhosis in patients with MELD score <12 and INR <1.2. BID, twice daily; CI, confidence interval; HE, hepatic encephalopathy; HR, hazard ratio; INR, international normalized ratio; MELD, Model for End-Stage Liver Disease.
Figure 2.
Figure 2.
Time to a first complication of cirrhosis experienced during the trial by treatment group. All complications of cirrhosis according to (a) presence or (b) absence of ascites at baseline; and non-HE complications of cirrhosis according to (c) presence or (d) absence of ascites at baseline. BID, twice daily; CI, confidence interval; HE, hepatic encephalopathy; HR, hazard ratio.
See this image and copyright information in PMC

References

    1. Ginés P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7: 122–128. - PubMed
    1. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217–231. - PubMed
    1. Starr SP, Raines D. Cirrhosis: diagnosis, management, and prevention. Am Fam Physician 2011; 84: 1353–1359. - PubMed
    1. Garcia-Tsao G, Lim JK; Members of the Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009; 104: 1802–1829. - PubMed
    1. Landis CS, Ghabril M, Rustgi V, et al. Prospective multicenter observational study of overt hepatic encephalopathy. Dig Dis Sci 2016; 61: 1728–1734. - PubMed

Associated data

LinkOut - more resources